Evotec

Evotec, a German-headquartered pharmaceutical preparation manufacturing company, has set ambitious climate targets and reports on its carbon emissions.

For 2023, Evotec reported total emissions of approximately 300.67 million kg CO2e. This included Scope 1 emissions of approximately 15.94 million kg CO2e, Scope 2 (market-based) emissions of approximately 11.67 million kg CO2e, and Scope 3 emissions of approximately 273.06 million kg CO2e. Key categories contributing to Scope 3 emissions were purchased goods and services (approximately 185.48 million kg CO2e) and capital goods (approximately 68.36 million kg CO2e).

Looking ahead, for 2024, Evotec anticipates Scope 1 emissions of about 13.76 million kg CO2e and Scope 2 (market-based) emissions of approximately 6.91 million kg CO2e. For 2025, they project Scope 1 emissions to be around 11.18 million kg CO2e and Scope 2 (market-based) emissions to be about 2.58 million kg CO2e.

Evotec has committed to Science Based Targets initiative (SBTi) aligned goals. This includes a commitment to reach net-zero greenhouse gas emissions across the value chain by 2045.

Near-term targets include:

• Reducing absolute Scope 1 and 2 GHG emissions by 50.4% by 2032, from a 2021 base year.
• Increasing active annual sourcing of renewable electricity from 25% in 2021 to 100% by 2026, and maintaining 100% renewable electricity sourcing through 2030.
• Reducing Scope 3 GHG emissions from purchased goods and services and capital goods by 72% per million EUR value added by 2032, from a 2021 base year.
• Ensuring that 80% of its suppliers, by emissions covering purchased goods and services and capital goods, will have science-based targets by 2027.

Long-term targets, towards their 2045 net-zero goal, involve:

• Reducing absolute Scope 1 and 2 GHG emissions by 95% by 2045, from a 2021 base year.
• Reducing Scope 3 GHG emissions by 97% per million EUR value added within the same timeframe.

Evotec's emissions data and climate commitments are directly reported by the company.